• Consequences of novel Coronavirus infection on brain health are significant, requiring frequent brain monitoring
• Brain diagnostics in infected patients extremely limited due to their severe physical illnesses; traditional EEG time consuming, exposes frontline workers to virus transmission risk
• BRSF’s sanitary disposable NeuroCap(TM) helps health care workers get quick, reliable insights into patient’s condition while minimizing cross-contamination risk

Brain Scientific (OTCQB: BRSF), a commercial-stage healthcare company providing next-gen solutions to the neurology market, is poised to offer a response to brain diagnostic challenges in the hospitals’ red zones amid the pandemic. As the Company describes in one of the recent articles published on the website, the consequences of the COVID-19 pandemic on brain health are significant (https://ibn.fm/fhYxm). 

While respiratory damage of novel Coronavirus is well reported, debilitating and even deadly neurological conditions may be affecting far more people infected with the virus. As the pandemic unravels and we learn more about the COVID-19, it is becoming clear that, although COVID-19 does not appear to directly attack nerve tissue, it is neurologically damaging. It is known to cause neurological injury in 1 out of 7 patients hospitalized with the infection (https://ibn.fm/aTUhK). The list of neurological diseases associated with COVID-19 infection is long and includes encephalopathy, Guillain-Barré syndrome, hemorrhagic stroke, ischemic stroke, meningoencephalitis, paralysis, and seizures. A growing body of evidence suggests that COVID-19 can have serious and potentially long-lasting effects on the brain — as many as 1 in 3 COVID-19 survivors experience neurological or a mental health disorder within six months of the infection (https://ibn.fm/Bop48). 

COVID-19 appears to cause neurological injury through three mechanisms, including hypoxemia — the state of very low blood oxygen levels causing encephalopathy and neurological damage; immune dysfunction causing “cytokine storm” and blood clots.

Neurological conditions associated with COVID-19 are challenging to diagnose. For example, the diagnosis of encephalopathy, one of the most frequently occurring neurological conditions in COVID-19, is mainly clinical and heavily hindered by the severe physical illnesses of hospitalized infected patients. Investigative procedures such as MRI, lumbar puncture and cerebrospinal fluid analysis are complicated to perform on ICU patients that are on supportive care measures such as mechanical ventilation and supplemental oxygenation.

The quest for a diagnostic procedure that may offer a response in this extremely difficult and limiting setting is still ongoing – but EEG may be able to offer a solution.

EEG could be a potentially helpful study to conduct on patients with suspected COVID-19 encephalopathy. Bedside EEG testing may reveal occult, subclinical seizure activity that would otherwise go unveiled. Still, traditional EEG testing is a time-consuming task that requires placing electrodes and measuring the patient’s head, which all prolongs exposure of frontline health workers to the deadly virus.

When fighting a highly contagious disease, disposable technology is vital. This is where NeuroCap(TM) and NeuroEEG(TM), the Company’s two FDA-cleared devices, can help. They offer cost-efficient, portable neurological monitoring. With sanitary, disposable EEG caps, BRSF’s revolutionary solution helps health care workers get a quick, reliable picture of a patient’s condition while ensuring that the virus is not spread through equipment. BRSF’s EEG caps designed for single use are also easy to place – within minutes – which helps shorten person-to-person exposure, minimizing cross-contamination risk between staff and patients.

For more information, visit the company’s website at www.BrainScientific.com/Invest-Now.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF 

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.